Investors
HCPs/Medical Affairs
News & Media
Arcutis Cares
Contact
Facebook
LinkedIn
Twitter
Instagram
Meaningful Innovation
Our Platform
Plaque Psoriasis
Atopic Dermatitis
Seborrheic Dermatitis
Scalp Psoriasis
Chronic Hand Eczema
Vitiligo
Alopecia Areata
Products
ZORYVE (roflumilast) cream
ZORYVE (roflumilast) foam
Arcutis' PDE4 Inhibitor
Pipeline
Our Growing Portfolio
Topical Roflumilast Cream
Topical Roflumilast Foam
ARQ-252
ARQ-255
ARQ-234
Scientific Publications
About Arcutis
Our Company
Our Leadership
Our Approach to ESG
Our Approach to Clinical Trials
Strategic Collaborators
Careers
Investors
HCPs/Medical Affairs
News & Media
Arcutis Cares
Contact
Facebook
LinkedIn
X
Instagram
News & Media
Press Releases
Back to News & Media
Arcutis Announces Positive Topline Data from Phase 2 Clinical Trial Evaluating ARQ-154 (Topical Roflumilast Foam) as a Potential Treatment for Seborrheic Dermatitis
PDF Version
Print Page
RSS Feeds
Email
Meaningful innovation at a glance.
Download our corporate fact sheet.
Download